Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dennis A. Eichenauer, Berthe M.P. Aleman, M. André, et al.
Annals of Oncology (2018) Vol. 29, pp. iv19-iv29
Open Access | Times Cited: 360

Showing 1-25 of 360 citing articles:

Antibody–drug conjugates come of age in oncology
Charles Dumontet, Janice M. Reichert, Peter D. Senter, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 8, pp. 641-661
Closed Access | Times Cited: 354
Glucocorticoids—All-Rounders Tackling the Versatile Players of the Immune System
Cindy Strehl, Lisa Ehlers, Timo Gaber, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 243
Hodgkin lymphoma
Joseph M. Connors, Wendy Cozen, Christian Steidl, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Closed Access | Times Cited: 157
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
Paul J. Bröckelmann, Helen Goergen, Ulrich Keller, et al.
JAMA Oncology (2020) Vol. 6, Iss. 6, pp. 872-872
Open Access | Times Cited: 147
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
Peter Borchmann, Annette Plütschow, Carsten Kobe, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 2, pp. 223-234
Closed Access | Times Cited: 134
EBUS-guided cryobiopsy in the diagnosis of thoracic disorders
Venerino Poletti, Simone Petrarulo, Sara Piciucchi, et al.
Pulmonology (2024) Vol. 30, Iss. 5, pp. 459-465
Open Access | Times Cited: 16
Gold nanoparticles as a drug delivery system for standard chemotherapeutics: A new lead for targeted pharmacological cancer treatments
Mohamed Yafout, Amine Ousaid, Youssef Khayati, et al.
Scientific African (2020) Vol. 11, pp. e00685-e00685
Open Access | Times Cited: 114
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Lesley J. Scott
Drugs (2017) Vol. 77, Iss. 4, pp. 435-445
Open Access | Times Cited: 107
Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines
Andrew Wirth, N. George Mikhaeel, Berthe M.P. Aleman, et al.
International Journal of Radiation Oncology*Biology*Physics (2020) Vol. 107, Iss. 5, pp. 909-933
Open Access | Times Cited: 105
Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals
Line K. Vibholm, Christina Valbirk Konrad, Mariane H. Schleimann, et al.
AIDS (2019) Vol. 33, Iss. 8, pp. 1315-1325
Closed Access | Times Cited: 82
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
Marie José Kersten, Julia Driessen, Josée M. Zijlstra, et al.
Haematologica (2020) Vol. 106, Iss. 4, pp. 1129-1137
Open Access | Times Cited: 81
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL
Zuoqiao Wu, Mary Nicoll, Robert J. Ingham
Experimental Hematology and Oncology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 77
Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients
Simone de Vries, Michael Schaapveld, Cècile P.M. Janus, et al.
JNCI Journal of the National Cancer Institute (2020) Vol. 113, Iss. 6, pp. 760-769
Open Access | Times Cited: 76
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Mehdi Hamadani, Graham P. Collins, Paolo F. Caimi, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 6, pp. e433-e445
Open Access | Times Cited: 71
Classical Hodgkin lymphoma
Pauline Brice, É. de Kerviler, Jonathan W. Friedberg
The Lancet (2021) Vol. 398, Iss. 10310, pp. 1518-1527
Open Access | Times Cited: 58
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
Stephen M. Ansell, Paul J. Bröckelmann, Gottfried von Keudell, et al.
Blood Advances (2023) Vol. 7, Iss. 20, pp. 6266-6274
Open Access | Times Cited: 39
Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment
Kari Hemminki, Janne Hemminki, Asta Försti, et al.
Leukemia (2023) Vol. 37, Iss. 4, pp. 854-863
Open Access | Times Cited: 28
FOXC1, the new player in the cancer sandbox
Fahed Elian, Elizabeth Yan, Michael A. Walter
Oncotarget (2017) Vol. 9, Iss. 8, pp. 8165-8178
Open Access | Times Cited: 62
Chemotherapy Associated Ovarian Failure
Davide Mauri, Ioanna Gazouli, George Zarkavelis, et al.
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 62
Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
Jesko Momotow, Sven Borchmann, Dennis A. Eichenauer, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 5, pp. 1125-1125
Open Access | Times Cited: 49
Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey
Charlotte Syrykh, Charlotte Chaouat, Elsa Poullot, et al.
Blood (2022) Vol. 140, Iss. 24, pp. 2573-2583
Closed Access | Times Cited: 35
The Impact of Systemic Oncological Treatments on the Fertility of Adolescents and Young Adults—A Systematic Review
Justine Himpe, Sander Lammerant, L. Van Den Bergh, et al.
Life (2023) Vol. 13, Iss. 5, pp. 1209-1209
Open Access | Times Cited: 20
FDG-PET imaging in hematological malignancies
Laia Valls, Chaitra Badve, Stefanie Avril, et al.
Blood Reviews (2016) Vol. 30, Iss. 4, pp. 317-331
Open Access | Times Cited: 57
Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study
Charlotte Maggen, Daan Dierickx, Pieternella J. Lugtenburg, et al.
The Lancet Haematology (2019) Vol. 6, Iss. 11, pp. e551-e561
Open Access | Times Cited: 54
PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
Marcus Unterrainer, Michael Ruzicka, Matthias P. Fabritius, et al.
European Radiology Experimental (2020) Vol. 4, Iss. 1
Open Access | Times Cited: 49
Page 1 - Next Page

Scroll to top